Core Viewpoint - New Gold Inc. reported strong financial and operational results for Q3 2025, achieving record production and free cash flow, primarily driven by the performance of the Rainy River mine and the New Afton mine [1][2][3]. Financial Performance - Q3 2025 revenue reached $462.5 million, a significant increase from $252.0 million in Q3 2024 [9]. - The company generated cash flow from operations of $301 million and record free cash flow of $205 million, marking a 225% quarter-over-quarter improvement [2][10]. - Net earnings for Q3 2025 were $142.3 million, compared to $37.9 million in Q3 2024, with adjusted net earnings of $199.5 million [11][12]. Production Highlights - Total gold production for Q3 2025 was 115,213 ounces, with Rainy River contributing 100,301 ounces, reflecting a 63% increase from Q2 2025 [6][10]. - New Afton produced 14,912 ounces of gold and 12.0 million pounds of copper, with the B3 cave performing above expectations [6][14]. - The company is on track to meet its annual production guidance of 325,000 to 365,000 ounces of gold [4][10]. Cost Metrics - All-in sustaining costs (AISC) for Q3 2025 were $966 per gold ounce sold, down from $1,195 in Q3 2024 [12][19]. - Cash costs per gold ounce sold on a by-product basis were $639, compared to $741 in Q3 2024 [12][19]. - Operating expenses per gold ounce sold were $874, a decrease from $1,021 in the previous year [12][19]. Debt Management - The company repaid $260 million in debt obligations during the quarter, including the full $150 million drawn on the credit facility [3][10]. - The company exited Q2 2025 with cash and cash equivalents of $123 million, strengthening its financial position [10][19]. Future Outlook - New Gold is well-positioned to achieve its full-year guidance, with capital spending and cash costs trending in line with expectations [4][5]. - The C-Zone at New Afton is on track for a production ramp-up in 2026, while Rainy River's operations are expected to generate significant free cash flow in the coming years [5][10]. Exploration and Growth - The exploration budget for New Afton has been increased to $22 million, with ongoing drilling confirming the potential for further mineralization at the K-Zone [16][19]. - The company anticipates a maiden K-Zone mineral resource estimate to be announced in early 2026 [16].

Group 1 - The markets are experiencing upward movement despite ongoing concerns, including a government shutdown that is approaching its fifth week without resolution [1] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions on trade ideas and weekly research updates [1] Group 2 - The article does not provide specific financial data or performance metrics related to the companies mentioned [2][3]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against F5, Inc. regarding possible violations of federal securities laws and unlawful business practices following a significant security breach [1][2]. Investigation Details - On October 15, 2025, F5 disclosed that a sophisticated nation-state threat actor had gained unauthorized access to its systems, including the BIG-IP product development environment and engineering knowledge management platform [2]. - The breach resulted in the exfiltration of certain files, including portions of the BIG-IP source code and information about undisclosed vulnerabilities [2]. - Following this announcement, F5's stock price dropped by $35.40, or approximately 10.70%, from $330.75 to $295.35 within a day [2]. Next Steps - Investors who purchased F5 shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations across state and federal courts [4].

Core Insights - First Quantum Minerals Ltd. reported a net loss of $48 million for Q3 2025, with an adjusted loss of $16 million, reflecting challenges despite operational improvements [1][3][33] - The company made significant progress in strengthening its balance sheet, including a $1 billion non-debt gold stream arrangement with Royal Gold and extending its debt maturity profile to 2029 [2][22][23] - Operationally, copper production increased by 15% quarter-over-quarter to 104,626 tonnes, driven by higher output from the Kansanshi and Sentinel mines [4][30] Financial Performance - Q3 2025 gross profit was $360 million, with EBITDA of $435 million, benefiting from improved production and higher realized metal prices [3][26] - Cash flows from operating activities reached $1,195 million, significantly higher than Q2 2025, primarily due to the gold streaming agreement [26][33] - Net debt decreased by $702 million to $4,751 million, attributed to the gold stream agreement and EBITDA contributions [26][33] Production and Operational Highlights - Total copper production for Q3 2025 was 104,626 tonnes, with Kansanshi producing 46,881 tonnes and Sentinel producing 51,336 tonnes [4][30] - Copper C1 cash cost decreased to $1.95 per lb, reflecting higher production volumes [4][34] - The company successfully completed the Kansanshi S3 Expansion project, contributing 6,136 tonnes of copper during the quarter [4][44] Updated Guidance - Copper production guidance for 2025 has been narrowed to 390,000 – 410,000 tonnes, while gold production guidance has been updated to 140,000 – 150,000 ounces [5][8] - Nickel production guidance has been adjusted to 18,000 – 23,000 tonnes, with total capital expenditure guidance reduced to $1,150 – $1,250 million [10][15] Cobre Panamá Update - The company completed remaining concentrate shipments from Cobre Panamá during the quarter, with the power plant expected to restart in Q4 2025 [2][40] - The Preservation and Safe Management plan was approved, allowing for the export of copper concentrate and the import of fuel [39][40] Environmental, Social, and Governance (ESG) Initiatives - The company has engaged in community initiatives, benefiting over 3,500 children and 5,000 community members through education, health, and infrastructure programs [43] - The THINK! Safety Program at Çayeli achieved over three years without a lost-time injury, reflecting a strong safety culture [52]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - GENFIT is participating in the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, showcasing its commitment to addressing rare and life-threatening liver diseases [1][10] Pipeline Developments - GENFIT will present new data on its lead program G1090N, a reformulation of nitazoxanide, focusing on its efficacy in treating Acute on-Chronic Liver Failure (ACLF) [2] - The company will also present data on SRT-015, an ASK1 inhibitor that reduces systemic inflammation and promotes immune defense mechanisms in ACLF models [3] - Additional presentations will cover CLM-022, an NLRP3 inflammasome inhibitor, and the effects of VS-01 on systemic inflammation and liver injury, although VS-01 has been discontinued in ACLF [3] Real-World Evidence and Biomarkers - An oral presentation will highlight real-world evidence characterizing patients admitted for acute decompensation, emphasizing management differences [4] - Posters will present new data on biomarkers for cirrhosis, including the effectiveness of single circulating biomarkers sVCAM-1 and TSP2 in detecting fibrosis progression [7] Collaborations and Additional Data - Ipsen will present data on Iqirvo® (elafibranor) in Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), supporting its efficacy and safety profile [11] - The data presented will underscore Iqirvo®'s potential in addressing disease progression and symptom burden in rare cholestatic liver diseases [8] Company Overview - GENFIT is dedicated to improving the lives of patients with rare liver diseases and has a strong focus on ACLF and related conditions [10][12] - The company has a rich history in liver disease research and has achieved accelerated approval for Iqirvo® in multiple jurisdictions [13][14]

Core Points - UniFirst Corporation has declared increased quarterly cash dividends of $0.365 per share for Common Stock and $0.292 per share for Class B Common Stock, payable on January 2, 2026 [1] Company Overview - UniFirst Corporation is a North American leader in supplying and servicing uniform and workwear programs, facility service products, and first aid and safety supplies [2] - The company operates five ISO-9001-certified manufacturing facilities and manages specialized garment programs for the cleanroom and nuclear industries [2] - With over 270 service locations and more than 300,000 customer locations, UniFirst outfits over 2 million workers daily [2]

HOUSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (“Itafos” or “the Company”) today announces that its financial results for Q3 2025 will be released after market close on Wednesday, November 5, 2025. An on-demand recorded webcast of management commentary that reviews the Q3 2025 financial results, provides an update on the business, and addresses analysts’ and investors’ recent frequently asked questions will be available on Monday, November 10, 2025 at 4:30 p.m. ET. The we ...

WINNIPEG, Manitoba--(BUSINESS WIRE)---- $EIF #TSX--Exchange Income Corporation Announces Early Redemption of 7 yr 5.25% Debentures due January 15, 2029. ...

Edison International reported a better-than-expected profit for the third quarter on Tuesday, as the utility benefited from higher rates for its services. ...